Gastroesophageal Reflux Disease Therapeutics Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Gastroesophageal Reflux Disease Therapeutics Market Expected To Reach $8.38 Billion By 2030 At 6.9% CAGR
The market for gastroesophageal reflux disease therapeutics has experienced robust expansion in recent years. Its value is projected to rise from $6.08 billion in 2025 to $6.42 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.6%. This historical growth has been driven by factors such as the increasing incidence of GERD, widespread use of proton pump inhibitors, heightened awareness regarding digestive health, the growth of hospital pharmacies, and the expanding elderly population.
The gastroesophageal reflux disease therapeutics market is anticipated to experience substantial expansion in the coming years. By 2030, its value is projected to reach $8.38 billion, reflecting a compound annual growth rate (CAGR) of 6.9%. This forecasted growth is driven by factors such as advancements in drug formulations, the rise of e-pharmacies, the growing use of telemedicine for gastrointestinal care, increased investment in precision medicine, and a rising preference for minimally invasive treatments. Key trends shaping this period include the emergence of personalized approaches to GERD management, the creation of innovative drug delivery systems, a growing demand for over-the-counter GERD medications, an intensified emphasis on gut health and microbiome balance, and the incorporation of remote patient monitoring with telehealth services.
Download A Free Sample Report For Comprehensive Market Insights:
Gastroesophageal Reflux Disease Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?
Self-medication practices are playing a major role in expanding the gastroesophageal reflux disease therapeutics market. This approach involves the use of drugs or other substances to manage a medical condition without seeking guidance from a healthcare professional. It is particularly effective in helping individuals identify and avoid trigger foods, manage stress, and quit smoking, all of which can lead to a notable improvement in GERD symptoms. As an example, in July 2024, the Proprietary Association of Great Britain (PAGB), a trade association based in the UK, reported that 64 million UK residents experienced at least one self-treatable condition in 2023. During this period, the proportion of cases where GP advice encouraged a shift to over-the-counter self-care rose from 58% in 2023 to 75% in 2024, while consumer confidence in using such medications climbed to 89%, an 8-point increase from the prior year. Consequently, the growing preference for self-medication is fueling the expansion of the gastroesophageal reflux disease therapeutics market.
Gastroesophageal Reflux Disease Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Gastroesophageal Reflux Disease Therapeutics Market Trends Reshaping Industry Growth
Within the gastroesophageal reflux disease therapeutics market, key players are focusing on creating innovative solutions, particularly wireless pH-capsule reflux testing systems designed for diagnosing and tracking GERD and related issues. For example, in April 2023, Laborie Medical Technologies Corp., a US-based medical testing equipment manufacturer, introduced the alpHaONE system. This wireless pH-capsule reflux testing device is specifically tailored to diagnose GERD, offering up to 96 hours of data monitoring to ensure precise and dependable results. The alpHaONE stands out with its ergonomic and compact design, featuring large, easy-to-press buttons and a fail-safe capsule delivery system engineered to protect the patient’s esophagus.
Gastroesophageal Reflux Disease Therapeutics Market Key Companies And Competitive Benchmarking
Major companies operating in the gastroesophageal reflux disease therapeutics market are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
Access The Complete Gastroesophageal Reflux Disease Therapeutics Market Report:
Gastroesophageal Reflux Disease Therapeutics Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
